AnHeart Licenses Two Clinical Stage Oncology Candidates from Daiichi Sankyo

Expanding Oncology Pipeline to Three Novel Molecules Following its Series A+ Financing Round

HANGZHOU, China and NEW YORK, Sept. 07, 2020 (GLOBE NEWSWIRE) -- AnHeart Therapeutics, Co., Ltd. (“AnHeart”), a clinical stage oncology company focused on underserved patients in global markets, has through its subsidiary AnHeart Therapeutics Inc. entered into license agreements with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”, TYO:4568) to acquire rights to two novel clinical stage oncology candidates (previously Daiichi Sankyo codes DS-1001 and DS-1205, now AnHeart codes AB-218 and AB-329, respectively). Under the terms of the agreements, Daiichi Sankyo is eligible to receive upfront payments, as well as development, regulatory and commercial milestone payments and royalties on net sales following market approval of the products.

AB-218 is a novel, potent, highly selective mutant IDH-1 inhibitor, which has high permeability of the blood-brain barrier and has demonstrated encouraging safety and efficacy signals in a Phase 1 trial of glioma patients. AnHeart will develop this compound for glioma and potentially other indications including acute myeloid leukemia (AML) and cholangiocarcinoma globally, except in Japan where Daiichi Sankyo will retain exclusive rights.

AB-329 is a novel, potent, highly selective AXL inhibitor, which AnHeart plans to test in combination with checkpoint inhibitors or third generation EGFR inhibitors in non-small cell lung cancer (NSCLC) as well as other solid tumors and hematological malignancies. AnHeart has global rights to the compound.

“We are extremely pleased with our highly productive relationship with Daiichi Sankyo,” said Junyuan (Jerry) Wang, PhD, Chief Executive Officer of AnHeart. “These two clinical stage assets represent the expansion of our initial taletrectinib agreement, and are both differentiated and promising with multiple potential therapeutic applications for the global markets. These new license agreements highlight AnHeart’s progress towards our strategic goal of building a pipeline of targeted oncology therapeutics to help serve patients with unmet needs all over the world.”

About AnHeart:
AnHeart Therapeutics Co., Ltd. (“AnHeart”) is a clinical stage biopharmaceutical company developing novel oncology therapies. AnHeart is headquartered in Hangzhou, China with offices in Beijing, Shanghai and has a subsidiary AnHeart Therapeutics Inc. in New York. Formed in November 2018, AnHeart is currently managed by biopharmaceuticals industry veterans and financially backed by venture capital funds.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates and our research and development programs; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our product candidates by physicians and patients; and (v) the timing or likelihood of regulatory filings and approvals. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. This Presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration or regulatory agencies in other countries. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

AnHeart Contact:
Akira Jing Liu, MD
Director of Business Development
(86) 137-0181-9470 (c)

Investor Relations Contact:
Irina Koffler
Managing Director
LifeSci Advisors, LLC
646-970-4681 (w)
917-734-7387 (c)

Primary Logo

Back to news